Serum potassium in the PARADIGM-HF trial.

ABSTRACT:

Aims

The associations between potassium level and outcomes, the effect of sacubitril-valsartan on potassium level, and whether potassium level modified the effect of sacubitril-valsartan in patients with heart failure and a reduced ejection fraction were studied in PARADIGM-HF. Several outcomes, including cardiovascular death, sudden death, pump failure death, non-cardiovascular death and heart failure hospitalization, were examined.

Methods and results

A total of 8399 patients were randomized to either enalapril or sacubitril-valsartan. Potassium level at randomization and follow-up was examined as a continuous and categorical variable (≤3.5, 3.6-4.0, 4.1-4.9, 5.0-5.4 and ≥5.5 mmol/L) in various statistical models. Hyperkalaemia was defined as K⁺  ≥5.5 mmol/L and

SUBMITTER: Ferreira JP 

PROVIDER: S-EPMC7756204 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature